Do analysts prefer ANEB or HCWB?

HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 1,382.95%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts plainly believe HCW Biologics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate HCWB or BIVI?

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 1,382.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe HCW Biologics is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HCWB or BIVI more profitable?

BioVie has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. BioVie's return on equity of -126.02% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -83.03% -262.33% -34.90% BioVie N/A -126.02% -108.88%

Does the media prefer HCWB or BIVI?

In the previous week, HCW Biologics had 4 more articles in the media than BioVie. MarketBeat recorded 6 mentions for HCW Biologics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.09 beat HCW Biologics' score of 0.00 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SYBX or HCWB?

HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 1,382.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts clearly believe HCW Biologics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, SYBX or HCWB?

HCW Biologics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synlogic $8K 1,760.79 -$23.36M -$0.06 N/A HCW Biologics $6.72M 0.55 -$7.96M -$27.60 N/A

Is SYBX or HCWB more profitable?

Synlogic has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Synlogic's return on equity of -26.47% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% HCW Biologics -83.03% -262.33% -34.90%

Does the media prefer SYBX or HCWB?

In the previous week, HCW Biologics had 5 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for HCW Biologics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.93 beat HCW Biologics' score of 0.00 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HCW Biologics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ENLV or HCWB?

In the previous week, HCW Biologics had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 6 mentions for HCW Biologics and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 equaled HCW Biologics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HCW Biologics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trading of HCW Biologics was halted at 10:29 AM EST due to "LULD Pause".

HCW Biologics (HCWB) Competitors

$2.02 +0.36 (+21.87%)

As of 10:52 AM Eastern

Compare

HCWB vs. ANEB, DYAI, BIVI, SYBX, and ENLV

Should you buy HCW Biologics stock or one of its competitors? HCW Biologics's main competitors and comparable companies include Anebulo Pharmaceuticals (ANEB), Dyadic International (DYAI), BioVie (BIVI), Synlogic (SYBX), and Enlivex Therapeutics (ENLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does HCW Biologics compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Anebulo Pharmaceuticals has a beta of -1.82, meaning that its share price is 282% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market.

Anebulo Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Anebulo Pharmaceuticals' return on equity of -74.57% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
HCW Biologics	-83.03%	-262.33%	-34.90%

In the previous week, HCW Biologics had 6 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 6 mentions for HCW Biologics and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled HCW Biologics'average media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
HCW Biologics	Neutral

HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 1,382.95%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts plainly believe HCW Biologics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HCW Biologics has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
HCW Biologics	$6.72M	0.55	-$7.96M	-$27.60	N/A

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 9.1% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

HCW Biologics beats Anebulo Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does HCW Biologics compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Dyadic International has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market.

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 594.44%. HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 1,382.95%. Given HCW Biologics' higher probable upside, analysts plainly believe HCW Biologics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HCW Biologics has a net margin of -83.03% compared to Dyadic International's net margin of -201.43%. HCW Biologics' return on equity of -262.33% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
HCW Biologics	-83.03%	-262.33%	-34.90%

In the previous week, HCW Biologics had 6 more articles in the media than Dyadic International. MarketBeat recorded 6 mentions for HCW Biologics and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.00 equaled HCW Biologics'average media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
HCW Biologics	Neutral

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dyadic International has higher earnings, but lower revenue than HCW Biologics. Dyadic International is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	5.60	-$7.36M	-$0.23	N/A
HCW Biologics	$6.72M	0.55	-$7.96M	-$27.60	N/A

Summary

HCW Biologics beats Dyadic International on 8 of the 13 factors compared between the two stocks.

How does HCW Biologics compare to BioVie?

HCW Biologics (NASDAQ:HCWB) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

BioVie has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. BioVie's return on equity of -126.02% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
BioVie	N/A	-126.02%	-108.88%

HCW Biologics has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market. Comparatively, BioVie has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 0.9% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 1,382.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe HCW Biologics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HCW Biologics has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.72M	0.55	-$7.96M	-$27.60	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

In the previous week, HCW Biologics had 4 more articles in the media than BioVie. MarketBeat recorded 6 mentions for HCW Biologics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.09 beat HCW Biologics' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

HCW Biologics beats BioVie on 10 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to Synlogic?

Synlogic (NASDAQ:SYBX) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, HCW Biologics had 5 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for HCW Biologics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.93 beat HCW Biologics' score of 0.00 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HCW Biologics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Synlogic has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Synlogic's return on equity of -26.47% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
HCW Biologics	-83.03%	-262.33%	-34.90%

HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 1,382.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts clearly believe HCW Biologics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 2.6% of Synlogic shares are owned by insiders. Comparatively, 9.1% of HCW Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HCW Biologics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,760.79	-$23.36M	-$0.06	N/A
HCW Biologics	$6.72M	0.55	-$7.96M	-$27.60	N/A

Synlogic has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

Summary

HCW Biologics beats Synlogic on 9 of the 16 factors compared between the two stocks.

How does HCW Biologics compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Enlivex Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

In the previous week, HCW Biologics had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 6 mentions for HCW Biologics and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 equaled HCW Biologics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HCW Biologics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enlivex Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Enlivex Therapeutics' return on equity of 248.08% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
HCW Biologics	-83.03%	-262.33%	-34.90%

Enlivex Therapeutics has higher earnings, but lower revenue than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
HCW Biologics	$6.72M	0.55	-$7.96M	-$27.60	N/A

Enlivex Therapeutics currently has a consensus target price of $247.50, suggesting a potential upside of 41,636.93%. HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 1,382.95%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Enlivex Therapeutics beats HCW Biologics on 10 of the 14 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.72M	$3.92B	$7.28B	$13.01B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.07	13.93	274.92	25.63
Price / Sales	0.55	1,458.02	673.28	90.00
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.40	15.03	10.34	6.27
Net Income	-$7.96M	-$22.82M	$3.49B	$360.12M
7 Day Performance	3.74%	-2.54%	-1.13%	-0.31%
1 Month Performance	-12.42%	-6.99%	-3.55%	-3.67%
1 Year Performance	-91.86%	29.64%	14.81%	5.14%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	2.9064 of 5 stars	$2.02 +21.9%	$30.00 +1,382.9%	-93.2%	$3.72M	$6.72M	N/A	35	News Coverage
ANEB Anebulo Pharmaceuticals	0.0365 of 5 stars	$0.36 +8.6%	N/A	-87.8%	$14.68M	N/A	N/A	4
DYAI Dyadic International	2.4078 of 5 stars	$0.40 -5.9%	$3.00 +645.2%	-61.6%	$14.67M	$1.33M	N/A	7	High Trading Volume
BIVI BioVie	1.0115 of 5 stars	$1.72 -1.7%	N/A	-11.4%	$14.53M	N/A	N/A	10
SYBX Synlogic	0.3465 of 5 stars	$1.17 flat	N/A	-33.7%	$14.33M	$8K	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. ANEB, DYAI, BIVI, SYBX, and ENLV

How does HCW Biologics compare to Anebulo Pharmaceuticals?

Summary

How does HCW Biologics compare to Dyadic International?

Summary

How does HCW Biologics compare to BioVie?

Summary

How does HCW Biologics compare to Synlogic?

Summary

How does HCW Biologics compare to Enlivex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. ANEB, DYAI, BIVI, SYBX, and ENLV

How does HCW Biologics compare to Anebulo Pharmaceuticals?

Which has more risk & volatility, ANEB or HCWB?

Is ANEB or HCWB more profitable?

Does the media favor ANEB or HCWB?

Do analysts prefer ANEB or HCWB?

Which has preferable valuation and earnings, ANEB or HCWB?

Do insiders & institutionals believe in ANEB or HCWB?

Summary

How does HCW Biologics compare to Dyadic International?

Which has more risk and volatility, DYAI or HCWB?

Do analysts prefer DYAI or HCWB?

Is DYAI or HCWB more profitable?

Does the media favor DYAI or HCWB?

Do insiders and institutionals believe in DYAI or HCWB?

Which has stronger earnings & valuation, DYAI or HCWB?

Summary

How does HCW Biologics compare to BioVie?

Is HCWB or BIVI more profitable?

Which has more volatility and risk, HCWB or BIVI?

Do insiders & institutionals hold more shares of HCWB or BIVI?

Do analysts rate HCWB or BIVI?

Which has stronger earnings & valuation, HCWB or BIVI?

Does the media prefer HCWB or BIVI?

Summary

How does HCW Biologics compare to Synlogic?

Does the media prefer SYBX or HCWB?

Is SYBX or HCWB more profitable?

Do analysts rate SYBX or HCWB?

Do institutionals and insiders hold more shares of SYBX or HCWB?

Which has better valuation & earnings, SYBX or HCWB?

Which has more volatility & risk, SYBX or HCWB?

Summary

How does HCW Biologics compare to Enlivex Therapeutics?

Which has more risk and volatility, ENLV or HCWB?

Does the media prefer ENLV or HCWB?

Is ENLV or HCWB more profitable?

Which has higher earnings and valuation, ENLV or HCWB?

Do analysts rate ENLV or HCWB?

Do institutionals & insiders hold more shares of ENLV or HCWB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools